BioCardia Files 8-K for Regulatory and Financial Updates

TL;DR

BioCardia dropped an 8-K for Reg FD and financials. Nothing earth-shattering in the snippet.

AI Summary

BioCardia, Inc. filed an 8-K on March 13, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's status and provides updated financial information. No specific new material events or financial figures were detailed in the provided excerpt.

Why It Matters

This filing serves as an official update for investors regarding BioCardia's regulatory compliance and financial reporting, ensuring transparency.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial statements and regulatory information, not indicating any immediate operational or financial distress.

Key Players & Entities

• BioCardia, Inc. (company) — Registrant
• March 13, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-38999 (filing_id) — Commission File Number
• 23-2753988 (tax_id) — IRS Employer Identification No.
• 320 Soquel Way (address) — Business and Mail Address

FAQ

Key Financial Figures

• $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Warrant

Filing Documents

• bcda20240312d_8k.htm (8-K) — 27KB
• ex_638695.htm (EX-99.1) — 13KB
• 0001437749-24-007538.txt ( ) — 189KB
• bcda-20240313.xsd (EX-101.SCH) — 4KB
• bcda-20240313_def.xml (EX-101.DEF) — 13KB
• bcda-20240313_lab.xml (EX-101.LAB) — 17KB
• bcda-20240313_pre.xml (EX-101.PRE) — 13KB
• bcda20240312d_8k_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 13, 2024, BioCardia, Inc. (the "Company") and StemCardia, Inc. ("StemCardia"), a biotechnology company developing cell and gene therapies engineered to repair the heart, issued a joint press release announcing a long-term partnership to advance StemCardia's investigational pluripotent stem cell product candidate for the treatment of heart failure. Under the partnership, BioCardia is the exclusive biotherapeutic delivery partner for StemCardia's cell therapy candidate through studies expected to result in FDA approval of an investigational new drug application and anticipated Phase I/II clinical development to follow. The information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 BioCardia, Inc. press release dated March 13, 2024 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: March 13, 2024

View Full Filing

View this 8-K filing on SEC EDGAR